Premium
Assessing tumor cytoarchitecture using multiecho DSC‐MRI derived measures of the transverse relaxivity at tracer equilibrium (TRATE)
Author(s) -
Semmineh Natenael B.,
Xu Junzhong,
Skinner Jack T.,
Xie Jingping,
Li Hua,
Ayers Gregory,
Quarles C. Chad
Publication year - 2015
Publication title -
magnetic resonance in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.696
H-Index - 225
eISSN - 1522-2594
pISSN - 0740-3194
DOI - 10.1002/mrm.25435
Subject(s) - cytoarchitecture , nuclear magnetic resonance , tracer , chemistry , physics , biology , nuclear physics , anatomy
Purpose In brain tumor dynamic susceptibility contrast (DSC)‐MRI studies, multiecho acquisition methods are used to quantify the dynamic changes in T 1 and T 2 * that occur when contrast agent (CA) extravasates. Such methods also enable the estimation of the effective tissue CA transverse relaxivity. The goal of this study was to evaluate the sensitivity of the transverse relaxivity at tracer equilibrium (TRATE) to tumor cytoarchitecture. Methods Computational and in vitro studies were used to evaluate the biophysical basis of TRATE. In 9L, C6, and human brain tumors, TRATE, the apparent diffusion coefficient ( ADC) , the CA transfer constant ( K trans ), the extravascular extracellular volume fraction ( v e ), and histological data were compared. Results Simulations and in vitro results indicate that TRATE is highly sensitive to variations in cellular properties such as cell size and density. The histologic cell density and TRATE values were significantly higher in 9L tumors as compared to C6 tumors. In animal and human tumors, a voxel‐wise comparison of TRATE with ADC , v e , and K trans maps showed low spatial correlation. Conclusion The assessment of TRATE is clinically feasible and its sensitivity to tissue cytoarchitectural features not present in other imaging methods indicate that it could potentially serve as a unique structural signature or “trait” of cancer. Magn Reson Med 74:772–784, 2015. © 2014 Wiley Periodicals, Inc.